ClinicalTrialsFinder
RecruitingNCT05934032

National Network Genomic Medicine Lung Cancer, Germany

Registry of the National Network Genomic Medicine Lung Cancer (nNGM), Linking Data on Molecular Diagnostics, Clinical Characteristics, Treatment Patterns and Outcomes of Subjects With Non-Small Cell Lung Cancer in Germany

Sponsor

Prof. Dr. Juergen Wolf

Enrollment

30,000 participants

Start Date

Apr 1, 2018

Study Type

OBSERVATIONAL

Conditions

Carcinoma, Non-Small Cell Lung

Summary

Registry of the national Network Genomic Medicine Lung Cancer (nNGM), linking data on molecular diagnostics, clinical characteristics, treatment patterns and outcomes of subjects with non-small cell lung cancer (NSCLC) from 23 specialized cancer centres and more than 400 general hospitals and oncological practices in Germany

Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Age ≥ 18 years
  • Histologically confirmed, locally advanced or metastatic NSCLC (Union for International Cancer Control \[UICC\] stage IIIb/IV; non-resectable NSCLC)
  • From 07/2023: histologically confirmed NSCLC stage Ib, II, III (UICC)

Exclusion Criteria1

  • Missing written informed consent

Interventions

OTHERobservational, non-interventional

observational, non-interventional

Locations(1)

University Hospital Cologne

Cologne, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05934032

Related Trials

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

NCT04389632154 locations

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

NCT0416507046 locations

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

NCT0416579847 locations

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

NCT0722702516 locations

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

NCT0723069145 locations